Historically low US brand price growth is one factor in a general slowdown in the annual growth rate of the global pharmaceutical market from 2019 through 2023, IQVIA forecasts in a new trends report.
The global pharmaceutical market is expected to grow at a 3%-6% compound annual growth rate over the next five years, exceeding $1.5tn by 2023, but that growth reflects a notable slowdown from the 6.3% growth rate over the past five years, according to a new trends report from the IQVIA Institute released Jan. 29.
The US and certain emerging markets will continue to be the key drivers of growth, with the US expected to...
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
